AJP - Endo Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Endocrinol Metab 281: E207-E216, 2001;
0193-1849/01 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (21)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hupfeld, C. J.
Right arrow Articles by Weiss, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hupfeld, C. J.
Right arrow Articles by Weiss, R. H.
Vol. 281, Issue 2, E207-E216, August 2001

TZDs inhibit vascular smooth muscle cell growth independently of the cyclin kinase inhibitors p21 and p27

Christopher J. Hupfeld1 and Robert H. Weiss2,3,4

Divisions of 1 Endocrinology and 2 Nephrology, Department of Internal Medicine, and 3 Cell and Developmental Biology Graduate Group, University of California, Davis 95616; and 4 Department of Veterans Affairs Northern California Health Care System, Mather, California 95655

The thiazolidenediones (TZDs) are commonly used to treat hyperglycemia in type 2 diabetes. Diabetes is associated with macrovascular disease, leading to accelerated atherosclerosis caused by aberrant vascular smooth muscle (VSM) cell proliferation. Although VSM cell proliferation is inhibited by the TZDs, the mechanism of this effect has not been established. Because of reports that the cyclin kinase inhibitors (CKIs) p21Waf1/Cip1 and p27Kip1 can exhibit both growth-inhibitory and growth-permissive effects in VSM cells, we asked whether alterations in these cell cycle regulatory proteins are the mechanism by which the TZDs inhibit VSM cell growth. We show that platelet-derived growth factor-BB increases p21 and p27 and that this increase is attenuated by TZDs. Surprisingly, when VSM cells were transfected with antisense oligodeoxynucleotides to p21 and p27, inhibition of DNA synthesis by TZDs occurred to the same degree as in control cells. Furthermore, the TZDs have inhibitory effects on cyclin D1 and cyclin E levels, suggesting another mechanism by which these drugs decrease VSM cell growth. These data suggest that the TZD-mediated reduction in CKI levels is not the sole mechanism for their antiproliferative effects. The observed decrease in levels of the G1 cyclins by the TZDs suggests a possible mechanism of VSM cell growth inhibition.

peroxisome proliferator-activated receptor-gamma ; cell cycle; proliferation; atherosclerosis; diabetes


This article has been cited by other articles:


Home page
 FASEB J.Home page
Y. P. Turmelle, O. Shikapwashya, S. Tu, P. W. Hruz, Q. Yan, and D. A. Rudnick
Rosiglitazone inhibits mouse liver regeneration
FASEB J, December 1, 2006; 20(14): 2609 - 2611.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Liu, C. Zang, M. H. Fenner, D. Liu, K. Possinger, H. P. Koeffler, and E. Elstner
Growth inhibition and apoptosis in human Philadelphia chromosome-positive lymphoblastic leukemia cell lines by treatment with the dual PPAR{alpha}/{gamma} ligand TZD18
Blood, May 1, 2006; 107(9): 3683 - 3692.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
C.J. Loy, S. Evelyn, F.K. Lim, M.H. Liu, and E.L. Yong
Growth dynamics of human leiomyoma cells and inhibitory effects of the peroxisome proliferator-activated receptor-{gamma} ligand, pioglitazone
Mol. Hum. Reprod., August 1, 2005; 11(8): 561 - 566.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Cell Physiol.Home page
L. Ragolia, T. Palaia, T. B. Koutrouby, and J. K. Maesaka
Inhibition of cell cycle progression and migration of vascular smooth muscle cells by prostaglandin D2 synthase: resistance in diabetic Goto-Kakizaki rats
Am J Physiol Cell Physiol, November 1, 2004; 287(5): C1273 - C1281.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
Y.-p. Fan and R. H. Weiss
Exogenous Attenuation of p21Waf1/Cip1 Decreases Mesangial Cell Hypertrophy as a Result of Hyperglycemia and IGF-1
J. Am. Soc. Nephrol., March 1, 2004; 15(3): 575 - 584.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Fan, A. D. Borowsky, and R. H. Weiss
An Antisense Oligodeoxynucleotide to p21Waf1/Cip1 Causes Apoptosis in Human Breast Cancer Cells
Mol. Cancer Ther., August 1, 2003; 2(8): 773 - 782.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
G. A. Wong, V. Tang, F. El-Sabeawy, and R. H. Weiss
BMP-2 inhibits proliferation of human aortic smooth muscle cells via p21Cip1/Waf1
Am J Physiol Endocrinol Metab, May 1, 2003; 284(5): E972 - E979.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
C. S. Elangbam, T. A. Brodie, H. Roger Brown, J. B. Nold, T. J. Raczniak, R. D. Tyler, R. M. Lightfoot, and H. G. Wall
Vascular Effects of GI262570X (PPAR-{gamma} agonist) in the Brown Adipose Tissue of Han Wistar Rats: A Review of 1-month, 13-week, 27-week and 2-year Oral Toxicity Studies
Toxicol Pathol, June 1, 2002; 30(4): 420 - 426.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online